TEM Stock - Tempus AI, Inc.
Unlock GoAI Insights for TEM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $693.40M | $531.82M | $320.67M | $257.85M | $188.00M |
| Gross Profit | $381.11M | $286.18M | $130.19M | $83.64M | $28.71M |
| Gross Margin | 55.0% | 53.8% | 40.6% | 32.4% | 15.3% |
| Operating Income | $-691,082,000 | $-196,083,000 | $-265,442,000 | $-243,711,000 | $-193,454,000 |
| Net Income | $-705,809,000 | $-214,118,000 | $-289,811,000 | $-259,192,000 | $-209,854,000 |
| Net Margin | -101.8% | -40.3% | -90.4% | -100.5% | -111.6% |
| EPS | $-4.60 | $-1.73 | $-1.97 | $-1.75 | $-1.49 |
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Visit WebsiteEarnings History & Surprises
TEMEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.05 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.17 | $-0.11 | +36.2% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.15 | $-0.18 | -20.0% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.27 | $-0.25 | +6.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.59 | $-0.63 | -6.8% | ✗ MISS |
Q2 2024 | Jun 17, 2024 | — | $-0.38 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.30 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.31 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.33 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.32 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.39 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.35 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.40 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.32 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.34 | — | — |
Q4 2016 | Nov 21, 2016 | $-0.32 | — | — | — |
Latest News
Frequently Asked Questions about TEM
What is TEM's current stock price?
What is the analyst price target for TEM?
What sector is Tempus AI, Inc. in?
What is TEM's market cap?
Does TEM pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to TEM for comparison